An analysis of the short- and long-term cost-effectiveness of starting biphasic insulin aspart 30 in insulin-naïve people with poorly controlled type 2 diabetes

Diabetes Research and Clinical Practice

Volumn 106, Issue 2, 2014, Pages 319-327

  Shafie, Asrul Akmal ^a   Gupta, Vishal ^b   Baabbad, Ranya ^c   Hammerby, Eva ^d   Home, Philip ^e  

^a SCHOOL OF PHYSICS   (Malaysia)

^b JASLOK HOSPITAL AND RESEARCH CENTRE   (India)

^c Pharmacoeconomics Centre of KSMC   (Saudi Arabia)

^d NOVO NORDISK A S   (Denmark)

^e NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

A1chieve; Biphasic insulin aspart 30; Cost effectiveness; Type 2 diabetes mellitus

Indexed keywords

CHOLESTEROL; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN ASPART; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; ANTIDIABETIC AGENT; BIPHASIC INSULIN; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; INSULIN ASPART, INSULIN ASPART PROTAMINE DRUG COMBINATION 30:70; ISOPHANE INSULIN;

ADULT; ALGERIA; ANALYSIS; ARTICLE; BLINDNESS; BODY MASS; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; CORE DIABETES MODEL; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DISEASE DURATION; ECONOMIC EVALUATION; EQ-5D; FEMALE; FOOT ULCER; GLYCEMIC CONTROL; HEALTH CARE COST; HEART INFARCTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INCREMENTAL COST EFFECTIVENESS RATIO; INDIA; INDONESIA; INSULIN TREATMENT; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; QUALITY ADJUSTED LIFE YEAR; QUESTIONNAIRE; SAUDI ARABIA; SELF MONITORING; SENSITIVITY ANALYSIS; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WORLD HEALTH ORGANIZATION; AGED; AUTOIMMUNE DISEASE; BLOOD; COST BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; ECONOMICS; METABOLISM; MIDDLE AGED; TIME; TREATMENT OUTCOME;

ADULT; AGED; ALGERIA; AUTOIMMUNE DISEASES; BIPHASIC INSULINS; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; FEMALE; HEALTH CARE COSTS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INDIA; INDONESIA; INSULIN ASPART; INSULIN, ISOPHANE; LIFE EXPECTANCY; MALE; MIDDLE AGED; QUALITY-ADJUSTED LIFE YEARS; SAUDI ARABIA; TIME FACTORS; TREATMENT OUTCOME;

EID: 84920604871     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2014.08.024     Document Type: Article

References (37)

1. Guariguata L., Whiting D.R., Hambleton I., Beagley J., Linnenkamp U., Shaw J.E. Global estimates of diabetes prevalence in adults for 2013 and projections for 2035 for the IDF Diabetes Atlas. Diabetes Res Clin Pract 2014, 103(2):137-149.
2. International Diabetes Federation Global guideline for type 2, diabetes. Diabetes Res Clin Pract 2014, 104(1):1-52.
3. Inzucchi S.E., Bergenstal R.M., Buse J.B., Diamant M., Ferrannini E., Nauck M., et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012, 55:1364-1379. American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD).
4. Home P., Naggar N.E., Khamseh M., Gonzalez-Galvez G., Shen C., Chakkarwar P., et al. An observational non-interventional study of people with diabetes beginning or changed to insulin analogue therapy in non-western countries: the A1cheive study. Diabetes Res Clin Pract 2011, 94:352-363.
5. Valensi P., Benroubi M., Borzi V., Gumprecht J., Kawamori R., Shaban J., et al. Initiating insulin therapy with, or switching existing insulin therapy to, biphasic insulin aspart 30/70 (NovoMix 30) in routine care: safety and effectiveness in patients with type 2 diabetes in the IMPROVE observational study. Int J Clin Pract 2009, 63:522-531. IMPROVE Study Group Expert Panel.
6. Davidson J.A., Liebl A., Christiansen J.S., Fulcher G., Ligthelm R.J., Brown P., et al. Risk for nocturnal hypoglycemia with biphasic insulin aspart 30 compared with biphasic human insulin 30 in adults with type 2 diabetes mellitus: a metaanalysis. Clin Ther 2009, 31:1641-1651.
7. Fonseca V., Davidson J., Home P., Snyder J., Jellinger P., Dyhr Toft A., et al. Starting insulin therapy with basal insulin analog or premix insulin analog in T2DM: a pooled analysis of treat-to-target trials. Curr Med Res Opin 2010, 26:1621-1628.
8. 1chieve observational study. Diabetes Res Clin Pract 2011, 94:364-370.
9. Palmer J.L., Knudsen M.S., Aagren M., Thomsen T.L. Cost-effectiveness of switching to biphasic insulin aspart from human premix insulin in a US setting. J Med Econ 2010, 13:212-220.
10. Valentine W.J., Palmer A.J., Lammert M., Nicklasson L., Foos V., Roze S. Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 versus insulin glargine in insulin naive type 2 diabetes patients: cost-effectiveness analysis in the UK setting. Curr Med Res Opin 2005, 21:2063-2071.
11. Brod M., Cobden D., Lammert M., Bushnell D., Raskin P. Examining correlates of treatment satisfaction for injectable insulin in type 2 diabetes: lessons learned from a clinical trial comparing biphasic and basal analogues. Health Qual Life Outcomes 2007, 5:8.
12. Baik S., Chacra A.R., Yuxiu L., White J., Güler S., Latif Z.A. Conducting cost-effectiveness analyses of type 2 diabetes in low- and middle-income countries: can locally generated observational study data overcome methodological limitations?. Diabetes Res Clin Pract 2010, 88(Suppl. 1):S17-S22.
13. Shillcutt S.D., Walker D.G., Goodman C.A., Mills A.J. Cost effectiveness in low- and middle-income countries: a review of the debates surrounding decision rules. PharmacoEconomics 2009, 27:903-917.
14. World Health Organization. Making Choices in Health: WHO Guide to Cost-Effectiveness Analysis. Geneva: World Health Organization, 2003.
15. Shah S.N., Litwak L., Haddad J., Chakkarwar P.N., Hajjaji I. The A1chieve study: a 60 000-person, global, prospective, observational study of basal, meal-time, and biphasic insulin analogs in daily clinical practice. Diabetes Res Clin Pract 2010, 88(Suppl. 1):S11-S16.
16. Majeed A., El-Sayed A.A., Khoja T., Alshamsan R., Millett C., Rawaf S. Diabetes in the Middle-East and North Africa: an update. Diabetes Res Clin Pract 2014, 103(2):218-222.
17. Palmer A.J., Roze S., Valentine W.J., Minshall M.E., Foos V., Lurati F.M., et al. Validation of the CORE Diabetes Model against epidemiological and clinical studies. Curr Med Res Opin 2004, 20:S27-S40.
18. Palmer A.J., Roze S., Valentine W.J., Minshall M.E., Foos V., Lurati F.M., et al. The CORE Diabetes Model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin 2004, 20:S5-S26.
19. Hnoosh A., Vega-Hernández G., Jugrin A., Todorova L. Direct medical costs of diabetes-related complications in Saudi Arabia. Value Health 2012, 15:A178.
20. Hnoosh A., Vega-Hernández G., Jugrin A., Todorova L. Direct medical management costs of diabetes-related complications in Algeria. Value Health 2012, 15:A179.
21. Todorova L., Hnoosh A., Bloomfield E., Shiu M.L. Estimating the direct medical costs associated with diabetes-related complications in Indonesia. Value Health 2012, 15:A662.
22. Todorova L., Hnoosh A., Korde G., Shiu M.L. Direct medical costs of diabetes-related complications in India. Value Health 2012, 15:A662.
23. Briggs A.H., Wonderling D.E., Mooney C.Z. Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. Health Econ 1997, 6:327-340.
24. The World Bank. World Bank Open Data. 2012. Available from: /(accessed02 January 2014). http://data.worldbank.org/.
25. World Health Organization. CHOosing Interventions that are Cost-Effective (WHO-CHOICE). 2009. Available from: (accessed 02 January 2014). http://www.who.int/choice/costs/CER_thresholds/en/index.html.
26. Gilmer T.P., O'Connor P.J., Rush W.A., Crain A.L., Whitebird R.R., Hanson A.M., et al. Predictors of health care costs in adults with diabetes. Diabetes Care 2005, 28:59-64.
27. Menzin J., Langley-Hawthorne C., Friedman M., Boulanger L., Cavanaugh R. Potential short-term economic benefits of improved glycemic control: a managed care perspective. Diabetes Care 2001, 24:51-55.
28. Ali M., White J., Lee C.H., Palmer J.L., Smith-Palmer J., Fakhoury W., et al. Therapy conversion to biphasic insulin aspart 30 improves long-term outcomes and reduces the costs of type 2 diabetes in Saudi Arabia. J Med Econ 2008, 11:651-670.
29. Ramachandran A., Ramachandran S., Snehalatha C., Augustine C., Murugesan N., Viswanathan V., et al. Increasing expenditure on health care incurred by diabetic subjects in a developing country: a study from India. Diabetes Care 2007, 30:252-256.
30. Alhowaish A.K. Economic costs of diabetes in Saudi Arabia. J Family Community Med 2013, 20:1-7.
31. Soewondo P., Ferrario A., Tahapary D.L. Challenges in diabetes management in Indonesia: a literature review. Global Health 2013, 9:63.
32. Zhang P., Zhang X., Brown J., Vistisen D., Sicree R., Shaw J., et al. Global healthcare expenditure on diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010, 87:293-301. (Erratum in: Diabetes Res Clin Pract 2011;92:301).
33. Li R., Bilik D., Brown M.B., Zhang P., Ettner S.L., Ackermann R.T., et al. Medical costs associated with type 2 diabetes complications and comorbidities. Am J Manag Care 2013, 19:421-430.
34. Ray J.A., Valentine W.J., Roze S., Nicklasson L., Cobden D., Raskin P., et al. Insulin therapy in type 2 diabetes patients failing oral agents: cost-effectiveness of biphasic insulin aspart 70/30 vs. insulin glargine in the US. Diabetes Obes Metab 2007, 9:103-113.
35. Valentine W.J., Goodall G., Aagren M., Nielsen S., Palmer A.J., Erny-Albrecht K. Evaluating the cost-effectiveness of therapy conversion to insulin detemir in patients with type 2 diabetes in Germany: a modelling study of long-term clinical and cost outcomes. Adv Ther 2008, 25:567-584.
36. Lee K.H., Seo S.J., Smith-Palmer J., Palmer J.L., White J., Valentine W.J. Cost-effectiveness of switching to biphasic insulin aspart 30 from human insulin in patients with poorly controlled type 2 diabetes in South Korea. Value Health 2009, 12(Suppl. 3):S55-S61.
37. Palmer J.L., Gibbs M., Scheijbeler H.W., Kotchie R.W., Nielsen S., White J., et al. Cost-effectiveness of switching to biphasic insulin aspart in poorly-controlled type 2 diabetes patients in China. Adv Ther 2008, 25:752-774.